Raymond James & Associates Has $642,000 Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Raymond James & Associates lowered its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 15.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,015 shares of the company’s stock after selling 3,344 shares during the quarter. Raymond James & Associates’ holdings in Pacira BioSciences were worth $642,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PCRX. Rubric Capital Management LP acquired a new stake in Pacira BioSciences in the 3rd quarter valued at approximately $14,102,000. Eagle Asset Management Inc. grew its holdings in Pacira BioSciences by 84.8% in the 3rd quarter. Eagle Asset Management Inc. now owns 136,393 shares of the company’s stock valued at $4,185,000 after buying an additional 62,597 shares during the last quarter. Rice Hall James & Associates LLC grew its holdings in Pacira BioSciences by 6.8% in the 3rd quarter. Rice Hall James & Associates LLC now owns 968,485 shares of the company’s stock valued at $29,713,000 after buying an additional 61,680 shares during the last quarter. Boston Partners grew its holdings in Pacira BioSciences by 105.4% in the 3rd quarter. Boston Partners now owns 108,509 shares of the company’s stock valued at $3,329,000 after buying an additional 55,679 shares during the last quarter. Finally, Glenmede Trust Co. NA grew its holdings in Pacira BioSciences by 17.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 347,222 shares of the company’s stock valued at $10,653,000 after buying an additional 51,877 shares during the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

Shares of PCRX opened at $25.90 on Thursday. The company has a current ratio of 5.24, a quick ratio of 4.17 and a debt-to-equity ratio of 0.59. Pacira BioSciences, Inc. has a 1 year low of $25.74 and a 1 year high of $48.60. The stock has a market cap of $1.20 billion, a P/E ratio of 31.98 and a beta of 0.76. The stock’s 50-day moving average price is $28.85 and its two-hundred day moving average price is $29.71.

Pacira BioSciences (NASDAQ:PCRX) last issued its earnings results on Thursday, February 29th. The company reported $0.71 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.71. Pacira BioSciences had a return on equity of 12.81% and a net margin of 6.22%. The firm had revenue of $181.24 million for the quarter, compared to analysts’ expectations of $180.60 million. On average, equities analysts predict that Pacira BioSciences, Inc. will post 2.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

PCRX has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $57.00 price objective on shares of Pacira BioSciences in a research report on Monday, March 4th. Needham & Company LLC restated a “buy” rating and set a $45.00 target price on shares of Pacira BioSciences in a research report on Tuesday, April 9th. Royal Bank of Canada cut their price objective on Pacira BioSciences from $53.00 to $45.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. JPMorgan Chase & Co. assumed coverage on Pacira BioSciences in a research report on Thursday, March 7th. They issued an “overweight” rating and a $45.00 price objective for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $57.00 price objective on shares of Pacira BioSciences in a research report on Thursday, February 8th. Eleven analysts have rated the stock with a buy rating, According to MarketBeat, Pacira BioSciences presently has a consensus rating of “Buy” and a consensus price target of $49.50.

Insiders Place Their Bets

In other Pacira BioSciences news, Director Gary W. Pace sold 1,066 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total value of $31,628.22. Following the completion of the transaction, the director now directly owns 140,384 shares of the company’s stock, valued at $4,165,193.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Gary W. Pace sold 90,000 shares of the company’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the completion of the transaction, the director now directly owns 22,127 shares of the company’s stock, valued at $677,086.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gary W. Pace sold 1,066 shares of the company’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total value of $31,628.22. Following the transaction, the director now directly owns 140,384 shares of the company’s stock, valued at $4,165,193.28. The disclosure for this sale can be found here. Company insiders own 6.60% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.